Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. Issue 4 (4th June 2021)

• Record Type: Journal Article
• Authors: Javaid, Faiza; Pilotti, Camilla; Camilli, Carlotta; Kallenberg, David; Bahou, Calise; Blackburn, Jack; R. Baker, James; Greenwood, John; Moss, Stephen E.; Chudasama, Vijay
• Is Part Of: RSC chemical biology. Volume 2:Issue 4(2021)
• Page Start: 1206
• Page End: 1220
• Publication Date: 2021-06-04
• Subjects: 572
• DOI: 10.1039/d1cb00104c
• Languages: English
• ISSNs: 2633-0679

Abstract

Abstract : LRG1 is present abundantly in the microenvironment of many tumours. LRG1 targeting through the reported non-internalising ADC presents a novel and effective proof-of-concept en route to improving the efficacy of cancer therapeutics. Abstract : Leucine-rich alpha-2-glycoprotein 1 (LRG1) is present abundantly in the microenvironment of many tumours where it contributes to vascular dysfunction, which impedes the delivery of therapeutics. In this work we demonstrate that LRG1 is predominantly a non-internalising protein. We report the development of a novel antibody–drug conjugate (ADC) comprising the anti-LRG1 hinge-stabilised IgG4 monoclonal antibody Magacizumab coupled to the anti-mitotic payload monomethyl auristatin E (MMAE) via a cleavable dipeptide linker using the site-selective disulfide rebridging dibromopyridazinedione (diBrPD) scaffold. It is demonstrated that this ADC retains binding post-modification, is stable in serum and effective in in vitro cell studies. We show that the extracellular LRG1-targeting ADC provides an increase in survival in vivo when compared against antibody alone and similar anti-tumour activity when compared against standard chemotherapy, but without undesired side-effects. LRG1 targeting through this ADC presents a novel and effective proof-of-concept en route to improving the efficacy of cancer therapeutics.